|
Theranostics 2018
“Cell-addictive” dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathwayDOI: 10.7150/thno.28295 Keywords: Parkinson's disease, dopaminergic neurons, EGCG, nanoparticles, α-synclein aggregation Abstract: α-synclein (αS) aggregation is a representative molecular feature of the pathogenesis of Parkinson's disease (PD). Epigallocatechin gallate (EGCG) can prevent αS aggregation in vitro. However, the in vivo effects of PD treatment are poor due to the obstacles of EGCG accumulation in dopaminergic neurons, such as the blood brain barrier and high binding affinities between EGCG and membrane proteins. Therefore, the key to PD treatment lies in visual examination of EGCG accumulation in dopaminergic neurons.
|